EUR 138.8
(-0.86%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 184.57 Thousand EUR | 3.44% |
2022 | - EUR | -77.04% |
2021 | - EUR | 45.62% |
2020 | 997 Thousand EUR | 23643.22% |
2019 | -1.09 Million EUR | -99.62% |
2018 | -118 Thousand EUR | 6.2% |
2017 | -151 Thousand EUR | 46.65% |
2016 | -5.82 Million EUR | -14.03% |
2015 | 214.11 Million EUR | 207.95% |
2014 | 69.52 Million EUR | -5.6% |
2013 | 73.65 Million EUR | 17720.57% |
2012 | -13.35 Million EUR | -12.97% |
2011 | -14.68 Million EUR | -101.0% |
2010 | -15.92 Million EUR | 9457.36% |
2009 | -6.31 Million EUR | -177.41% |
2008 | 509 Thousand EUR | 389.42% |
2007 | -16.9 Million EUR | -99.93% |
2006 | 156.63 Million EUR | -48.4% |
2005 | 303.55 Million EUR | 129.71% |
2004 | 132.14 Million EUR | 2.54% |
2003 | 128.87 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -878.54 Thousand EUR | 0.0% |
2023 Q4 | -900.66 Thousand EUR | 0.0% |
2023 Q2 | -993.32 Thousand EUR | 0.0% |
2023 FY | - EUR | -102.17% |
2022 FY | - EUR | -77.04% |
2022 Q2 | -781 Thousand EUR | 0.0% |
2022 Q4 | -1.11 Million EUR | 0.0% |
2021 Q2 | -508 Thousand EUR | 0.0% |
2021 FY | - EUR | 45.62% |
2021 Q4 | -389 Thousand EUR | 0.0% |
2020 Q4 | -1.64 Million EUR | 0.0% |
2020 FY | - EUR | 23643.22% |
2020 Q2 | -481 Thousand EUR | 0.0% |
2019 FY | - EUR | -99.62% |
2019 Q2 | 147.75 Million EUR | 0.0% |
2019 Q4 | 137.06 Million EUR | 0.0% |
2018 FY | - EUR | 6.2% |
2018 Q1 | 71.88 Million EUR | -52.24% |
2018 Q4 | 87.94 Million EUR | 0.0% |
2018 Q2 | 198.03 Million EUR | 175.51% |
2017 Q2 | 155.99 Million EUR | 130.46% |
2017 FY | - EUR | 46.65% |
2017 Q4 | 150.5 Million EUR | 0.0% |
2017 Q1 | 67.69 Million EUR | -10.76% |
2016 FY | - EUR | -14.03% |
2016 Q4 | 75.85 Million EUR | 0.0% |
2016 Q2 | 108.46 Million EUR | 133.64% |
2016 Q1 | 46.42 Million EUR | -62.37% |
2015 FY | - EUR | 207.95% |
2015 Q3 | 54.08 Million EUR | -41.74% |
2015 Q4 | 123.36 Million EUR | 128.1% |
2015 Q2 | 92.83 Million EUR | 71.64% |
2015 Q1 | 54.08 Million EUR | 174.76% |
2014 Q4 | 19.68 Million EUR | 13.25% |
2014 FY | - EUR | -5.6% |
2014 Q3 | 17.38 Million EUR | -58.44% |
2014 Q1 | 17.38 Million EUR | -44.73% |
2014 Q2 | 41.82 Million EUR | 140.63% |
2013 Q2 | 15.29 Million EUR | -16.93% |
2013 Q1 | 18.41 Million EUR | 0.0% |
2013 Q4 | 31.45 Million EUR | 70.8% |
2013 Q3 | 18.41 Million EUR | 20.38% |
2013 FY | - EUR | 17720.57% |
2012 Q1 | 23.05 Million EUR | 0.0% |
2012 FY | - EUR | -12.97% |
2012 Q3 | 23.05 Million EUR | 0.0% |
2012 Q4 | 18.41 Million EUR | -20.13% |
2012 Q2 | 23.05 Million EUR | 0.0% |
2011 Q3 | 17.55 Million EUR | 0.0% |
2011 FY | - EUR | -101.0% |
2011 Q4 | 23.05 Million EUR | 31.36% |
2011 Q2 | 17.55 Million EUR | 0.0% |
2011 Q1 | 17.55 Million EUR | 0.0% |
2010 Q4 | 17.55 Million EUR | 90.42% |
2010 Q1 | 9.21 Million EUR | 0.0% |
2010 FY | - EUR | 9457.36% |
2010 Q3 | 9.21 Million EUR | 0.0% |
2010 Q2 | 9.21 Million EUR | 0.0% |
2009 Q4 | 9.21 Million EUR | -77.43% |
2009 Q1 | 40.84 Million EUR | 0.0% |
2009 Q2 | 40.84 Million EUR | 0.0% |
2009 FY | - EUR | -177.41% |
2009 Q3 | 40.84 Million EUR | 0.0% |
2008 Q1 | -266 Thousand EUR | 0.0% |
2008 Q3 | -266 Thousand EUR | 0.0% |
2008 Q2 | -266 Thousand EUR | 0.0% |
2008 Q4 | 40.84 Million EUR | 15454.23% |
2008 FY | - EUR | 389.42% |
2007 Q2 | 10.21 Million EUR | 0.0% |
2007 Q4 | -266 Thousand EUR | -102.6% |
2007 Q1 | 10.21 Million EUR | 0.0% |
2007 Q3 | 10.21 Million EUR | 0.0% |
2007 FY | - EUR | -99.93% |
2006 Q1 | 121.2 Million EUR | 0.0% |
2006 Q2 | 121.2 Million EUR | 0.0% |
2006 Q3 | 121.2 Million EUR | 0.0% |
2006 Q4 | 10.21 Million EUR | -91.57% |
2006 FY | - EUR | -48.4% |
2005 FY | - EUR | 129.71% |
2005 Q4 | 121.2 Million EUR | 59.72% |
2005 Q3 | 75.88 Million EUR | 0.0% |
2005 Q2 | 75.88 Million EUR | 0.0% |
2005 Q1 | 75.88 Million EUR | 0.0% |
2004 Q4 | 75.88 Million EUR | 129.71% |
2004 Q2 | 33.03 Million EUR | 0.0% |
2004 Q3 | 33.03 Million EUR | 0.0% |
2004 Q1 | 33.03 Million EUR | 0.0% |
2004 FY | - EUR | 2.54% |
2003 Q3 | 32.21 Million EUR | 0.0% |
2003 FY | - EUR | 0.0% |
2003 Q2 | 32.21 Million EUR | 0.0% |
2003 Q1 | 32.21 Million EUR | 0.0% |
2003 Q4 | 33.03 Million EUR | 2.54% |
2002 Q4 | 32.21 Million EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
ABIONYX Pharma SA | -3.29 Million EUR | 105.61% |
ABIVAX Société Anonyme | -133.2 Million EUR | 100.139% |
Adocia SA | -22.73 Million EUR | 100.812% |
Aelis Farma SA | -6.34 Million EUR | 102.908% |
Biophytis S.A. | -13.8 Million EUR | 101.337% |
Advicenne S.A. | -6.24 Million EUR | 102.956% |
genOway Société anonyme | 6.35 Million EUR | 97.094% |
IntegraGen SA | -52.5 Thousand EUR | 451.544% |
Medesis Pharma S.A. | -3.84 Million EUR | 104.8% |
Neovacs S.A. | -8.44 Million EUR | 102.184% |
NFL Biosciences SA | -4.04 Million EUR | 104.558% |
Plant Advanced Technologies SA | 72.53 Thousand EUR | -154.475% |
Quantum Genomics Société Anonyme | -2.87 Million EUR | 106.423% |
Sensorion SA | -22.31 Million EUR | 100.827% |
Theranexus Société Anonyme | -7.38 Million EUR | 102.499% |
TME Pharma N.V. | -5.07 Million EUR | 103.639% |
Valbiotis SA | -6.95 Million EUR | 102.654% |
TheraVet SA | -517.33 Thousand EUR | 135.677% |
Valerio Therapeutics Société anonyme | -18.91 Million EUR | 100.976% |
argenx SE | -199.5 Million EUR | 100.093% |
BioSenic S.A. | -6.79 Million EUR | 102.716% |
Celyad Oncology SA | -7.76 Million EUR | 102.378% |
DBV Technologies S.A. | -79.53 Million EUR | 100.232% |
Galapagos NV | 51.03 Million EUR | 99.638% |
Genfit S.A. | -28.05 Million EUR | 100.658% |
GeNeuro SA | -14.31 Million EUR | 101.289% |
Hyloris Pharmaceuticals SA | -14.98 Million EUR | 101.232% |
Innate Pharma S.A. | -7.57 Million EUR | 102.436% |
Inventiva S.A. | -101.84 Million EUR | 100.181% |
MaaT Pharma SA | -19.74 Million EUR | 100.935% |
MedinCell S.A. | -20.04 Million EUR | 100.921% |
Nanobiotix S.A. | -34.01 Million EUR | 100.543% |
Onward Medical N.V. | -35.23 Million EUR | 100.524% |
Oryzon Genomics S.A. | -4.43 Million EUR | 104.163% |
OSE Immunotherapeutics SA | -23.26 Million EUR | 100.793% |
Oxurion NV | -16.72 Million EUR | 101.103% |
Pharming Group N.V. | 4.98 Million EUR | 96.294% |
Poxel S.A. | -12.17 Million EUR | 101.515% |
GenSight Biologics S.A. | -21.73 Million EUR | 100.849% |
Transgene SA | -27.02 Million EUR | 100.683% |
UCB SA | 1.26 Billion EUR | 99.985% |
Valneva SE | -64.51 Million EUR | 100.286% |
Vivoryon Therapeutics N.V. | -28.35 Million EUR | 100.651% |